Thanks to the efforts of @IMI_Prefer, the EMA has issued a positive draft opinion on the use of patient preference to inform regulatory decisions on new drugs—a move that could help companies better meet patient needs on.pfizer.com/3xGUJmy #PFEColleague bit.ly/3DdtJfw